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0939-4753/ª 2014 Elsevier B.V. Open access unAbstract Background and aims: In Italy, the reimbursed use of incretin mimetics and incretin
enhancers was subject to enrollment of patients into a web-based system recording the general
demographic and clinical data of patients. We report the utilization data of glucagon-like peptide
1 (GLP1) receptor agonists and dipeptidylpeptidase-4 (DPP4) inhibitors in clinical practice as re-
corded by the Italian Medicines Agency (AIFA) Monitoring Registry.
Methods and results: From February 2008 to August 2010, 75,283 patients with type 2 diabetes
were entered into the registry and treated with exenatide, sitagliptin, or vildagliptin. The treat-
ment was administered to patients in a wide range of ages (75 years, n Z 6125 cases), body
mass index (BMI) (35 kg/m2, n Z 22,015), and metabolic control (HbA1c  11% ((96 mmol/
mol), n Z 3151). Overall, 1116 suspected adverse drug reactions were registered, including 12
cases of acute pancreatitis (six on exenatide). Hypoglycemic episodes mainly occurred in combi-
nation with sulfonylureas. Treatment discontinuation for the three drugs (logistic regression
analysis) was negatively associated with the male gender and positively with baseline HbA1c,
diabetes duration, and, limitedly to DPP-4 inhibitors, with BMI. Treatment discontinuation
(including loss to follow-up, accounting for 21e26%) was frequent. Discontinuation for treatment
failure occurred in 7.7% of cases (exenatide), 3.8% (sitagliptin), and 4.1% (vildagliptin), respec-
tively, corresponding to 27e40% of all discontinuations, after excluding lost to follow-up. HbA1c
decreased on average by 0.9e1.0% (9 mmol/mol). Body weight decreased by 3.5% with exenatide
and by 1.0e1.5% with DPP-4 inhibitors.
Conclusions: In the real world of Italian diabetes centers, prescriptions of incretins have been
made in many cases outside the regulatory limits. Nevertheless, when appropriately utilized, in-
cretins may grant results at least in line with pivotal trials.
ª 2014 Elsevier B.V. Open access under CC BY-NC-ND license.nes Agency (AIFA), Ofﬁce for Pharmaceutical Policy, Via del Tritone 181, 00187 Rome, Italy.
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A progressive intensiﬁcation of treatment is mandatory in
type 2 diabetes whenever lifestyle intervention fails to
maintain metabolic control [1]. All major guidelines agree
on administering metformin as the initial treatment, when
tolerated and not contraindicated, but there is no
consensus on second-line add-on treatment, in the case of
unsatisfactory metabolic control. [2e5].
In the past decade, injectable glucagon-like peptide-1
receptor agonists (GLP-1RAs) and orally administered in-
hibitors of dipeptidylpeptidase-4 (DPP-4Is) entered the
diabetes arena [6,7]. Since the initial marketing authori-
zation as add-on therapies, these drugs have been granted
extension of indications to include ﬁrst-line monotherapy
and combination with insulin. However, their best place in
therapy remains uncertain [8]. In controlled clinical trials,
both GLP-1RAs and DPP-4Is, combined with metformin,
produce similar improvements in glycemic control as
other second-line treatments, with no negative effects on
body weight and overall hypoglycemia [9,10]. However,
only a few systematic analyses of long-term clinical data
are available on large patients’ cohorts [11,12], capturing
treatment effects and prescription trends in the
community.
In February 2008, the Italian Medicines Agency (AIFA)
approved the reimbursed use of exenatide, sitagliptin, and
vildagliptin, subject to enrollment of patients into a web-
based system to monitor the appropriateness of use, safety
proﬁle, and effects on metabolic control and body weight.
We report the results of the ﬁrst 30-month monitoring, as
derived from the AIFA Monitoring Registry. Of note, ﬁxed-
dose associations of sitagliptin and vildagliptin with met-
formin were made available along the years; in the present
report, their use is considered equivalent to the combi-
nation use of the individual compounds. Focus is given to
the clinical characteristics of patients, drug safety, and
reasons for treatment discontinuation. An analysis of the
percentage of patients reaching HbA1c targets over time is
also provided, to help clinicians tailor treatment on pa-
tients’ characteristics.
Methods
The AIFA Anti-diabetics Monitoring registry
A monitoring system has long been operative in Italy to
register the use of several therapeutic agents in a wide
range of diseases (oncology, neurodegenerative disorders,
inﬂammatory diseases, etc.). The incretin-mimetic and
incretin-enhancer AIFA Registry was the ﬁrst example of a
monitoring tool in a highly prevalent disease largely
managed by general practitioners (GPs). Access to therapy
was allowed through diabetes specialist centers after
registration of patients in a web-based system provided by
CINECA, a consortium of Italian universities and the Na-
tional Research Council. The system monitored the regis-
tration process all over the country and the uploading of
clinical data, and gave access to reimbursement by theNational Health Service (NHS). An information letter was
sent to the GPs of registered patients to create a ﬂow of
information inside the therapeutic network. Follow-up
data were uploaded at 3- (vildagliptin) or 4-month (exe-
natide and sitagliptin) intervals for the ﬁrst year, and every
6 months thereafter (Supplemental Figure S1).
The case report form included demographic and clinical
characteristics, the association with other glucose-
lowering agents, and the treatment effects on HbA1c and
body weight. The reasons for withdrawal and treatment
change were also recorded, and a webpage was available
to register adverse drug reactions (ADRs) according to
Medical Dictionary for Regulatory Activities (MedDRA)
classiﬁcation. The details of the ADRs were sent to the
pharmacovigilance system online or by fax, and the most
severe ADRs were locally checked by direct phone inter-
view with specialists.
The AIFA Anti-diabetics Registry was set up in February
2008. In August 2010, exenatide, sitagliptin, and vilda-
gliptin were made available without registration.
Statistical analysis
A descriptive analysis of the population was initially car-
ried out through a multiple-record/-patient approach. To
assess the differences in baseline characteristics among
patients’ groups, Mood’s median test was used for
continuous variables and the chi-squared test for cate-
gorical variables. Combination therapies with other anti-
diabetic drugs were also recorded.
The safety proﬁles were assessed by incidence rates
(IRs) of ADRs, expressed as 1000 person-years (sum of the
duration of exposure from entry to event, discontinuation
or data lock in August 2010). The relative risks (RRs) of
hypoglycemic events were also calculated in relation to the
associated glucose-lowering therapy.
In multivariate logistic regression analysis, all cases with
recorded discontinuation (any cause) or lost to follow-up
(L-FU) were classiﬁed as “treatment discontinuation”
(dependent variable, worst-case scenario). The indepen-
dent variables were the demographic and clinical charac-
teristics at enrollment (gender, age, body mass index (BMI),
waist circumference, fasting glucose, HbA1c, fasting C-
peptide, and associated glucose-lowering drugs). The waist
circumference (less informative than BMI) and fasting
glucose or C-peptide (less informative than HbA1c) were
excluded. In a sensitivity test, the analyses were repeated in
a subset of patients from centers compliant to follow-up
>80% (exenatide, n Z 10,388; sitagliptin, n Z 18,278; vil-
dagliptin, n Z 7068; total L-FU, n Z 2746 (7.7%)).
The probability of reaching the target value of HbA1c
<7% (53 mmol/mol) at the 3e4- and 8e9-month follow-
up was tested by logistic regression in separate models
for the three different drugs, having HbA1c at baseline as
independent variable. In a sensitivity analysis, a less
stringent glycemic control of HbA1c <8% (64 mmol/mol)
was assessed.
All analyses were performed by CINECA by means of the
open-source R Project for Statistical Computing &
1348 S. Montilla et al.Graphics, Version 2.15.0/2012 (www.r-project.org), devel-
oped at Bell Laboratories (now Alcatel-Lucent, Paris,
France) for multivariate statistics and models, and by
means of an SQL developer (Oracle) for the descriptive part
of the analysis.
Results
Patient population and baseline characteristics
A total of 77,864 records (38,811 on sitagliptin, 21,064 on
exenatide, and 17,989 on vildagliptin), corresponding to
75,283 patients, were registered by 3741 diabetes spe-
cialists in 1278 centers, either hospital (n Z 790) or
community based (n Z 488), distributed throughout Italy.
On average, 16.5/10,000 inhabitants aged 18 were
included (from 8.2 to 28.8 in different Italian regions).
The patients belonged to a fairly heterogeneous group,
including a high proportion of cases scarcely represented
in the trials supporting the marketing authorization of the
three medicinal products. Over 50% of cases on exenatide
and approximately 20% on DPP4-Is had severe obesity
(BMI  35 kg/m2); exenatide patients exhibited higher
median HbA1c and a greater percentage of cases with very
poor metabolic control (HbA1c  11%, 97 mmol/mol).
Elderly patients (75 years, n Z 6125) constituted
approximately 10% of the DPP-4I-treated cases (Table 1A;
Supplemental Figure S2).
Metformin was the background therapy in most cases,
with/without concomitant sulfonylureas. Glitazones were
rarely used, reﬂecting the Italian market. Monotherapy
with sitagliptin was registered in <1% of cases (Table 1B).
Adverse drug reactions
During the 30-month observation period, 1116 ADRs were
registered. The median time to ADR was 2.06, 2.85, and
3.87 months on exenatide, sitagliptin, and vildagliptin,
respectively. Complete and partial recovery was observed
in 717 and 179 cases, respectively; 103 cases did not
recover, and late complications were registered in 13. NoTable 1A Baseline demographic/clinical data of the population with di
glucose-lowering agents.
Exenatide (n Z 21,064)
Mean SD
Age (years) 58.9 9.9
Duration of diabetes (years) 10.0 15.4
Body mass index (kg/m2) 36.1 6.8
Waist circumference (cm) 115.9 14.4
Fasting glucose (mg/dL) 187.8 49.8
HbA1c (%) [mmol/mol] 8.8 [73] 1.3 [14]
Fasting C-peptide (ng/mL) 3.2 1.6
N %
Male gender 10,109 48.0
Age > 75 years 723 3.4
BMI > 35 10,835 51.4
HbA1c > 11% (>97 mmol/mol) 1496 7.1follow-up was available in 102 cases and two patients died.
ADRs did not lead to treatment discontinuation only in 90
cases; after stopping the treatment, drug use was restarted
in 100 cases.
ADRs were classiﬁed as severe in 77 cases (6.9%),
particularly with exenatide (six acute pancreatitis, seven
vomiting/nausea, and four renal failures, corresponding to
an IR of 0.334, 0.390, and 0.223/1000 person-years,
respectively) (Table 2). Three cases of acute pancreatitis
occurred on sitagliptin and three more on vildagliptin (IRs:
0.097 and 0.221/1000 person-years, respectively). In
addition, non-severe pancreatitis/elevated pancreatic en-
zymes were recorded in 48 cases (19 with exenatide, 16
with sitagliptin, and 13 with vildagliptin).
Hypoglycemic episodes were reported in 1085
exenatide-treated patients, 608 on sitagliptin, and 207 on
vildagliptin, with IRs of 20.6, 6.3, and 4.6/1000 person-
years, respectively. Sulfonylureas, either alone or com-
bined with metformin, increased the risk of hypoglycemia.
The RR during add-on to sulfonylureas, compared with
add-on to metformin, was 2.96 (95% conﬁdence interval
(CI), 2.33e3.50) on exenatide, 2.99 (95% CI, 2.45e3.64) on
sitagliptin, and 1.84 (95% CI, 1.20e2.69) on vildagliptin. In
add-on to sulfonylurea þ metformin, the RRs further
increased to 3.76 (95% CI, 3.24e4.36) and 2.94 (95% CI,
2.39e3.61) for exenatide and sitagliptin, respectively (not
authorized for vildagliptin).
Treatment switching and discontinuation
Treatment switching (to one of the monitored drug or to
other treatments) was recorded in 3.5%, 7.2%, and 7.7% of
cases on exenatide, sitagliptin, and vildagliptin, respec-
tively. The most common change was from sitagliptin to
exenatide (n Z 652).
There were 9608/21,064 discontinuations (including L-
FU) on exenatide (45.6%), 13,578/38,811 on sitagliptin
(35%), and 7056/17,989 on vildagliptin (39.2%)
(Supplemental Figure S3). The rates of L-FU were 26.1%,
21.2%, and 24.5%, respectively. Discontinuation for treat-
ment failure occurred in 7.7%, 3.8%, and 4.1% of cases,abetes enrolled in the AIFA Anti-diabetics Monitoring Registry with
Sitagliptin (n Z 38,811) Vildagliptin (n Z 17,989)
Mean SD Mean SD
61.7 10.4 61.9 10.4
9.1 7.1 8.2 6.5
30.8 5.7 30.5 5.5
104.6 13.1 104.4 12.6
170.8 41.6 171.9 41.1
8.3 [67] 1.1 [12] 8.2 [66] 1.1 [12]
3.0 1.6 3.3 1.7
N % N %
20,446 52.7 9741 54.1
3666 9.4 1736 9.7
7870 20.3 3300 18.3
1139 2.9 516 2.9







N % N % N %
No associationa 0 0 3.87 0.1 0
Metformin 10,691 50.8 25,116 64.7 15,289 85
Sulfonylureas 1323 6.3 1843 4.7 2062 11.5
Sulfonylureas + metformin 9050 43.0 9824 25.3 ea ea
Glitazones ea ea 1624 4.2 638 3.5
Repaglinide 1450 6.9 276 0.7 ea ea
Acarbose 260 1.2 225 0.5 72 0.4
In individual cases, background therapy could vary in the course of the observation. Please note that patients could be treated with more than
one active principle; therefore, the sum of the percentages of cases may exceed 100%.
a Off-label according to marketing authorization.
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DPP-4Is were added to metformin as a second-line treat-
ment, compared to third-line treatments. After excluding
L-FUs, treatment failure accounted for 27e40% of all
discontinuations.Table 2 List of all severe ADRs and corresponding IR (in 1000 person-ye
Event Exenatide Si
No. IRa 95% CI N
Acute pancreatitis 6 0.334 (0.157e0.650) 3
Vomiting/nausea 7 0.390 (0.192e0.727) 1
Renal failure 4 0.223 (0.090e0.488) 0
Colon cancer 1 0.056 (0.013e0.205) 2
Epileptic convulsions 2 0.111 (0.034e0.310) 0
Abdominal pain 2 0.111 (0.034e0.310) 0
Severe hypoglycemia 1 0.056 (0.013e0.205) 1
Pneumonia 0 (0.000e0.140) 2
Breast cancer 1 0.056 (0.013e0.205) 2
Visual loss 0 (0.000e0.140) 1
Colon adenoma 0 (0.000e0.140) 0
Anaphylactic reaction/shock 1 0.056 (0.013e0.205) 1
Anemia 0 (0.000e0.140) 0
Cardiac failure 1 0.056 (0.013e0.205) 0
Atrioventricular block 1 0.056 (0.013e0.205) 0
Renal carcinoma 2 0.111 (0.034e0.310) 0
Cervix carcinoma 1 0.056 (0.013e0.205) 0
Coronary disease/Infarction 2 0.111 (0.034e0.310) 0
Cholecystitis 0 (0.000e0.140) 0
Cholestasis 0 (0.000e0.140) 1
Acute dermatitis 1 0.056 (0.013e0.205) 0
Gastric hemorrhage 0 (0.000e0.140) 1
Abdominal hernia 1 0.056 (0.013e0.205) 0
Atrial ﬁbrillation 1 0.056 (0$013e0.205) 0
Liver dysfunction 0 (0.000e0.140) 0
Acute gastroenteritis 1 0.056 (0.013e0.205) 0
Congestive gastropathy 1 0.056 (0.013e0.205) 0
Ictus/cerebral
hemorrhage/ischemia
1 0.056 (0.013e0.205) 1
Leukemia/lymphoma 0 (0.000e0.140) 2
Urticaria 2 0.111 (0.034e0.310) 0
Bladder cancer 0 (0.000e0.140) 0
Pericardial effusion 0 (0.000e0.140) 1
Gastric ulcer 1 0.056 (0.013e0.205) 0
Other 2 0.111 (0.034e0.310) 1
Total 43 2.397 (1.781e3.162) 20
a Incidence rate (IR) Z # event (N )/person-time at risk (T ).The male gender was associated with a lower risk of
discontinuation, while older age was a risk factor for
discontinuation on exenatide and a protective factor on
DPP-4Is (Table 3). Both baseline HbA1c and diabetes
duration were associated with a higher risk ofars) reported in the AIFA Anti-diabetics Monitoring Registry.
tagliptin Vildagliptin
o. IRa 95% CI No. IRa 95% CI
0.097 (0.035e0.234) 3 0.221 (0.080e0.533)
0.032 (0.008e0.119) 0 (0.000e0.185)
(0.000e0.081) 1 0.074 (0.018e0.272)
0.065 (0.020e0.180) 1 0.074 (0.018e0.272)
(0.000e0.081) 0 (0.000e0.185)
(0.000e0.081) 0 (0.000e0.185)
0.032 (0.008e0.119) 0 (0.000e0.185)
0.065 (0.020e0.180) 0 (0.000e0.185)
0.065 (0.020e0.180) 0 (0.000e0.185)
0.032 (0.008e0.119) 0 (0.000e0.185)
(0.000e0.081) 1 0.074 (0.018e0.272)
0.032 (0.008e0.119) 0 (0.000e0.185)






(0.000e0.081) 1 0.074 (0.018e0.272)
0.032 (0.008e0.119) 0 (0.000e0.185)
(0.000e0.081) 1 0.074 (0.018e0.272)
0.032 (0.008e0.119) 0 (0.000e0.185)
(0.000e0.081) 0 (0.000e0.185)
(0.000e0.081) 0 (0.000e0.185)
(0.000e0.081) 2 0.147 (0.046e0.411)
(0.000e0.081) 0 (0.000e0.185)
(0.000e0.081) 0 (0.000e0.185)
0.032 (0.008e0.119) 1 0.074 (0.018e0.272)
0.065 (0.020e0.180) 1 0.074 (0.018e0.272)
(0.000e0.081) 0 (0.000e0.185)
(0.000e0.081) 1 0.074 (0.018e0.272)
0.032 (0.008e0.119) 0 (0.000e0.185)
(0.000e0.081) 0 (0.000e0.185)
0.032 (0.008e0.119) 0 (0.000e0.185)
0.645 (0.421e0.960) 14 1.034 (0.619e1.639)
Table 3 Factors associated with treatment discontinuation (any reason, including lost to follow-up) for the three drugs in the AIFA Anti-diabetics




OR (95% CI) No. events/
No. at riska
OR (95% CI) No. events/
No. at riska
OR (95% CI)
Male sex 4088/9394 0.89 (0.84e0.94) 5236/18,201 0.92 (0.88e0.96) 2898/8613 0.91 (0.86e0.98)
Age (years/10) 8802/19,566 1.14 (1.11e1.17) 10,191/34,421 0.90 (0.88e0.92) 5477/15,841 0.97 (0.94e1.00)
HbA1c at baseline (%) 8802/19,566 1.09 (1.07e1.11) 10,191/34,421 1.13 (1.11e1.15) 5477/15,841 1.13 (1.10e1.17)
Diabetes duration (years/10) 8802/19,566 1.14 (1.10e1.19) 10,191/34,421 1.00 (0.97e1.03)b 5477/15,841 1.11 (1.06e1.17)
Body mass index (kg/m2/5) 8802/19,566 0.80 (0.76e0.85) 10,191/34,421 1.03 (1.01e1.05) 5477/15,841 1.03 (1.00e1.06)b
a No. at risk includes only cases with HbA1c values ranging from 7% (53 mmol/mol) to 16% at baseline (151 mmol/mol). No. events includes
only cases for which a complete description of associated factors was reported.
b Not signiﬁcant (a Z 0.05).
1350 S. Montilla et al.discontinuation (not statistically signiﬁcant for sitagliptin).
Higher BMI at baseline was associated with a greater risk
of discontinuation on DPP-4Is and a lower risk on exena-
tide. The add-on to metformin was associated with a low
risk of discontinuation on exenatide (odds ratio (OR), 0.80;
95% CI, 0.76e0.85) and a high risk on DPP-4i (OR, 1.21; 95%
CI, 1.16e1.26). On the contrary, add-on to sulfonylureas,
with/without metformin, carried a high risk of discontin-
uation on exenatide (OR, 1.25; 95% CI, 1.18e1.32) and a low
risk on DPP-4i (OR, 0.72; 95% CI, 0.69e0.75).
In the subset of centers accurately compliant to follow-
up, the analysis did not provide systematically different
results (Supplementary Table 1).Effect on glycemic control and body weight
On exenatide, absolute HbA1c decreased on average by
0.99% (0.9 mmol/mol) and body weight by 3.5% from
baseline to the last available follow-up. The corresponding
variations for sitagliptin and vildagliptin were 0.88% and
0.94% (0.8e0.9 mmol/mol) for HbA1c, and around 1.0%
for body weight. The probability of reaching the HbA1c
target of 7% (53 mmol/mol) or the secondary target of 8%
(64 mmol/mol), after 3e4 or 8e9 months, decreased
rapidly with increasing baseline HbA1c, with <20% prob-
ability for baseline values >9% (>75 mmol/mol) (Fig. 1).
The number of cases at target with baseline HbA1c >11%
was much lower for sitagliptin and vildagliptin than for
exenatide, and the conﬁdence interval of the estimate
much larger.
In the subset of centers compliant to follow-up, the
probability of achieving the desired target was not
dependent on age or BMI, but it was inversely related to
baseline HbA1c and to the use of incretin mimetics/DPP-
4Is as third-line therapy. The add-on to metformin and
treatment duration (not on vildagliptin) increased the
probability of reaching the target (Supplementary Table 2).Figure 1 Probability of achieving the targets of metabolic control
(HbA1c <7%, lower lines; <8%, upper lines) at 3e4 months (continuous
lines) or 8e9 months (broken lines) as function of entry HbA1c values.Discussion
The AIFA Monitoring Registry of exenatide, sitagliptin, and
vildagliptin, collecting data on the use, safety, and effec-
tiveness of incretin mimetics/DPP-4Is, represents asigniﬁcant step forward in the post-marketing evaluation
of new or innovative medicines.
The safety proﬁles of exenatide, sitagliptin, and vilda-
gliptin in Italian clinical practice were similar to those
recorded in registration trials and recently reviewed [12].
Although favored by online registration, the total number
of ADRs was relatively low e but much higher than that
usually observed in post-marketing surveillance e despite
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were registered, with only one case of heart failure with
DPP-4Is [13]. The decision of the regulatory Italian Agency
(AIFA) to limit the reimbursement of incretin-based ther-
apies to diabetes specialists in a well-deﬁned monitoring
system might have favored an accurate selection of pa-
tients also in the community setting, limiting adverse
reactions.
Two ADRs are of particular signiﬁcance: pancreatitis
and hypoglycemia. The association of exenatide and sita-
gliptin with pancreatitis was documented since 2006 and
prompted close monitoring [14,15]. Later, the potential risk
appeared to be increased by diabetes per se; post-approval
studies have documented cases associated with incretin
use, but a causal relationship between treatment and
pancreatitis was neither proved nor excluded [16e20]. In
the registry, a few additional reports of non-severe
pancreatitis or simply raised levels of pancreatic en-
zymes were also recorded, without differences between
drugs. When these non-adjudicated ADRs were summed
up to severe pancreatitis, the total incidence of pancreatic
events was in the range reported in the general population
with diabetes and should be considered in the context of
the notoriety bias generated by alerts. A 2013 compre-
hensive review of preclinical and clinical data on pancre-
atic safety by the European Medicines Agency concluded
that the concerns on the risk of pancreatitis should not be
minimized [21]. Later, the publication of two large car-
diovascular outcome DPP-Is trials [13,22] and epidemio-
logical data [23] stiﬂed the debate; a 2014 joint Food and
Drug Administration (FDA)eEuropean Medicines Agency
(EMA) assessment concluded with a low-risk [24] but
suggested continuous capture of data.
As expected, exenatide and DPP4-I add-ons to metfor-
min were accompanied by low rates of hypoglycemia [25].
On the contrary, a two-to threefold increase in hypogly-
cemia was observed in combination with sulfonylureas,
both with and without metformin, but very few cases were
recorded as severe ADRs, requiring hospital admission.
These data are in keeping with registration studies and
with recent clinical trials showing that DPP4-Is are asso-
ciated with very low rates of hypoglycemia when com-
bined with metformin [26], despite similar or only
moderately inferior glucose-lowering efﬁcacy compared to
sulfonylureas.
The analysis of discontinuation rates and metabolic ef-
fects may give hints for an appropriate use of these drugs
in the community. This approach seems sound, as
conﬁrmed by a sensitivity analysis in a subset of selected
centers with adherence to follow-up 80%
(Supplementary Tables 1 and 2). As expected, the discon-
tinuation rates of all drugs increased systematically with
higher baseline HbA1c. They also increased with age for
exenatide, not for gliptins, indicating a preferential use of
oral agents in elderly subjects for whom a less strict
metabolic target may be preferred [3,4,27]. On the con-
trary, weight loss might be the reason for the lower
discontinuation rates of exenatide with increasing BMI,
despite injections and higher baseline HbA1c.Two subpopulations, with limited safety data in regis-
tration studies, deserve particular attention. The AIFA
Registry included many patients aged 70; in a few of
them, gastrointestinal symptoms associated with exena-
tide were the precipitating factors of acute renal failure, a
side effect to be considered in frail patients. DPP-4Is were
demonstrated to be safe in a meta-analysis on patients
aged 65, as well as in a systematic review, and vilda-
gliptin was shown to be effective and safe also in subjects
with diabetes aged 75 [6,9,27]. Future analyses of the
elderly Italian cohort will throw light on the efﬁcacy of
DPP-4I in the elderly. Similarly, the very large group with
morbid obesity in the AIFA Registry will offer a unique
opportunity to test the effects of incretin-based therapies
in these patients, where metabolic control remains difﬁ-
cult and the use of insulin may be critical, because it
further increases body weight.
In our database, the effectiveness of incretin-based
add-on therapies on HbA1c and body weight was similar
to that reported in a review of head-to-head trials [28],
but these results should be taken with caution, consid-
ering that the high rate of L-FUs inﬂates effectiveness.
HbA1c was reduced on average by 0.9e1.0% (9 mmol/mol)
in the general dataset, also in relation to HbA1c at base-
line, with much larger effects in subjects with poor
metabolic control. In the AIFA Registry, exenatide and
DPP-4Is were also prescribed to subjects with very poor
metabolic control, above the levels where insulin is rec-
ommended by international guidelines [4]. Such pre-
scribing approach may be explained by the opportunity
to test these new drugs across the whole spectrum of
disease, or as an extreme attempt before prescribing in-
sulin. Fig. 1 provides an immediate picture of the possi-
bility of attaining speciﬁc HbA1c targets with incretin-
based therapies in clinical practice, emphasizing the
predictive value of baseline metabolic control. This ﬁgure
may help clinicians forecast the results of treatment in
their next patient, as modulated by other variables (i.e.,
age, BMI, diabetes duration, and background treatment),
as reported in Supplementary Table 2. The observation
that several patients with HbA1c in the range 9e11%
(75e97 mmol/mol) may reach an acceptable metabolic
control with a low incidence of adverse reactions,
including hypoglycemic events, is clinically relevant. Drug
effectiveness should always be considered in the context
of existing therapies [29], safety, cost, therapeutic inertia
[30], and the beneﬁcial effects of intensive lifestyle
counseling, which remains mandatory at any step of
intensiﬁed treatment. Notably, in frail patients, a patient-
centered approach and progressively less challenging
targets are proposed by international guidelines, to avoid
the risk of adverse events. [4].
Our study presents limitations and strengths. First, the
major limitation is an observation period of only 30
months, too short to draw deﬁnite conclusions on long-
term efﬁcacy (i.e., effects on diabetic complications). Sec-
ond, due to its observational nature, baseline differences,
and high rates of L-FU, any comparisons of safety,
discontinuation, and effect on metabolic and weight
1352 S. Montilla et al.control among the three drugs should be made with
extreme caution. Third, given the purpose of the AIFA
Registry, there was no comparator-treated group.
Conversely, the main strength is the very large and het-
erogeneous diabetes cohort, including the complete data-
set from an entire European nation, where drugs were
used under strict regulatory access, requiring online
registration for reimbursement.
In conclusion, data on the compliance, safety, and
effectiveness of incretin-based therapies derived from the
AIFA Registry, while not capturing any new safety signal,
provide a comprehensive framework for health-care pro-
viders to regulate the use of these drugs in the community.
These data might be useful to address several important
points, including the independent effect of baseline HbA1c
on its decline, the safety and effectiveness in subjects with
diabetes over 75, and the effectiveness of incretins e also
including liraglutide and saxagliptin from August 2010 e
in the large cohort of obese subjects with BMI >35. These
analyses will be carried out when the monitoring data will
be available in the new and updated in-house web plat-
form currently being developed. Whenever effective stra-
tegies of lifestyle changes preliminary to any further step
in treatment intensiﬁcation fail, the implementation of
new treatments, including incretin-based therapies,
should be dictated by solid data on long-term safety and
effectiveness in the context of available drugs for type 2
diabetes, favoring a patient-centered approach. [4].
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